Omeros (OMER) Return on Capital Employed (2011 - 2026)
Omeros (OMER) posted Return on Capital Employed of 42.7% for Q1 2026, up 38.23% sequentially from 69.14% in Q4 2025, and up 5151.0% YoY from 0.81% in Q1 2025.
Omeros (OMER) Return on Capital Employed (2011 - 2026) Analysis & Trends
Omeros has reported Return on Capital Employed for 16 years, with the latest figure at 42.7% in Q1 2026.
- Quarterly Return on Capital Employed rose 5151.0% year-over-year to 42.7% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 42.7% (up 5151.0% YoY) and the FY2025 annual result came in at 54.99%, up 1229.0% from the prior year.
- Return on Capital Employed grew to 42.7% in Q1 2026 per OMER's latest filing, from 69.14% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 37.6% in Q1 2023 and troughed at 113.07% in Q3 2025.
- A 5-year average of 59.69% and a median of 48.12% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2022 and 2025: Return on Capital Employed jumped 13376 bps in 2022, then plunged 5098 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 42.12% in 2022, then fell by 2 bps to 43.03% in 2023, then slumped by 80 bps to 77.41% in 2024, then gained by 11 bps to 69.14% in 2025, then jumped by 38 bps to 42.7% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 42.7%, 69.14%, and 113.07% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Omeros | 1.24 Bn | 1.24 Bn | 27.73 Mn | -38.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -38.02% |
| Mar 31, 2026 | -42.70% |
| Dec 31, 2025 | -69.14% |
| Sep 30, 2025 | -113.07% |
| Jun 30, 2025 | -102.81% |
| Mar 31, 2025 | -94.21% |
| Dec 31, 2024 | -77.41% |
| Sep 30, 2024 | -62.09% |
| Jun 30, 2024 | -55.16% |
| Mar 31, 2024 | -48.12% |
| Dec 31, 2023 | -43.03% |
| Sep 30, 2023 | -45.42% |
| Jun 30, 2023 | -41.85% |
| Mar 31, 2023 | -37.60% |
| Dec 31, 2022 | -42.12% |
| Sep 30, 2022 | -45.88% |
| Jun 30, 2022 | -48.66% |
| Mar 31, 2022 | -45.48% |
| Dec 31, 2021 | -79.07% |
| Sep 30, 2021 | -179.65% |